Ionis Pharmaceuticals, Inc., a US-based biopharmaceutical company, has made significant strides in discovering and developing RNA-targeted therapeutics. The company's portfolio includes a range of medicines such as SPINRAZA, used for the treatment of Spinal Muscular Atrophy (SMA) in both pediatric and adult patients, TEGSEDI - an antisense injection for patients with Polyneuropathy caused by Hereditary Transthyretin Amyloidosis and WAYLIVRA, an antisense medication for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. Ionis Pharmaceuticals is also developing several medicines for various indications in Phase 3 clinical trials for many diseases. These include Eplontersen, Olezarsen, Donidalorsen, ION363, Tofersen, Pelacarsen, and Bepirovirsen. The company also develops Cimdelirsen, IONIS-FB-LRx, and ION224 to inhibit the production of growth hormone receptor, complement factor B and the alternative complement pathway, and diacylglycerol acyltransferase 2, respectively. Ionis Pharmaceuticals has entered into strategic collaboration with Biogen to address neurological disorders and secured collaboration and license agreements with Metagenomi, Inc., AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is headquartered in Carlsbad, California.
Ionis Pharmaceuticals's ticker is IONS
The company's shares trade on the NASDAQ stock exchange
They are based in Carlsbad, California
There are 501-1000 employees working at Ionis Pharmaceuticals
It is ionispharma.com
Ionis Pharmaceuticals is in the Healthcare sector
Ionis Pharmaceuticals is in the Biotechnology industry
The following five companies are Ionis Pharmaceuticals's industry peers: